News on CRISPR, gene editing, RNAi in genetics, genomics, and molecular diagnostics.
The Boston-based synthetic biology firm said it will use the funds to grow its cell programing platform, which it will make available to startups.
The blood-based test is designed to detect changes in levels of microRNAs that are enriched in specific brain regions affected by Alzheimer's disease.
The firm saw steady growth in its research reagents and screening businesses, and a 155 percent revenue increase in its bioproduction unit.
The Genome Sensor — the first product Cardea will market under the Nanosens brand — will allow the user to Google a genome using a single guide RNA.
The companies also launched an early-access program for their first CRISPR-Chip-based product, the Genome Sensor.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.
This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.